A number of clinical, angiographic, and procedural factors predispose to the occurrence of<unk><unk> .<unk>  of<unk><unk>  can be classified into anatomic variables, procedure related variables and clinical variables. A new entity which has been recently recognised and is being increasingly studied in relation to<unk><unk>  is hyporesponsiveness to antiplatelet agents.
Procedure related variables:
Procedure related variables include<unk>  underexpansion, margin dissections, incomplete wall apposition, residual inflow and outflow disease, overlapping<unk> , polymer materials and use of self expanding or coil<unk> s.
Anatomic variables:
Lesion-specific factors that increase the likelihood of<unk><unk>  include a residual dissection at the margin of the<unk> , impaired flow into or out of the<unk> , small<unk>  diameters (<3 mm), long<unk>  lengths, and treatment of an acute myocardial infarction.
Clinical variables:
Clinical variables include acute myocardial infarction, clopidogrel noncompliance and discontinuation, hyporesponsiveness to antiplatelet agents, higher baseline platelet count, diabetes mellitus, renal failure, congestive heart failure, prior radiation brachytherapy.
In addition to these,<unk>  implantation for off-label indication of both DES and BMS(such as restenotic lesions, bypass graft lesions, left main<unk>  artery disease, as well as ostial, bifurcated, and totally occluded lesions) has been associated with higher rates of ischemic complications, including<unk><unk> , as compared with standard indications.
In a case control study of 145 patients with<unk><unk>  by Rinaldi et al, presence of angiographic thrombus prior to<unk> ing, greater total<unk>  length, higher baseline platelet count, acute MI indication, the use of a self expanding or coil<unk> , and GpIIb-IIIa exposure were identified as the strongest<unk>  of<unk><unk> .
In another study by Marroquin et al to compare the outcomes in bare-metal versus drug-elting<unk> s for off-label indications showed that one year after intervention, there were no significant differences in the adjusted risk of death or myocardial infarction in patients with drug eluting<unk> s as compared with those with bare metal<unk> s. These findings implicate that the poorer outcome observed after<unk> ing for off-label indications are related to patient and lesion characteristics but not to the<unk>  itself. Therefore, large randomized clinical trial are needed to further study the use of DES for off label versus standard indications.
Predictors of coronary stent thrombosis
Spontaneous coronary artery dissection classification
Chronic stable angina risk stratification
Appropriate use criteria for revascularization
European society of cardiology guidelines classification scheme
Ventricular fibrillation epidemiology and demographics
PCI in the angulated or tortuous lesion
Canadian cardiovascular society classification of angina pectoris